TX-MAVENIR
11.6.2024 15:01:33 CEST | Business Wire | Press release
Mavenir, the cloud-native network infrastructure provider building the future of networks, today announced that it has pioneered a breakthrough Operations Co-Pilot that harnesses the power of generative AI (GenAI) to improve service-level agreements (SLAs) and optimize operational efficiency for communications service providers (CSPs). The innovation, which has been developed in collaboration with NVIDIA and Amazon Web Services (AWS), showcases the potential of GenAI to effectively define a Service Assurance AI/Ops Platform – reducing the burden on operations, support and maintenance teams and enhancing their ability to meet SLAs.
Mavenir’s Operations Co-Pilot for RAN Service Assurance (RSA) automates network troubleshooting, enabling mobile network operators to rapidly and accurately anticipate network issues and address detected network impairments before they become critical. The Operations Co-Pilot significantly reduces manual debugging effort, development and maintenance lead times to enhance IT operations, service availability and delivery for increasingly complex mobile networks.
Utilizing the power of GenAI with large language models (LLMs) trained on detailed key performance indicators (KPIs), counters, logs and traces from network infrastructure, Mavenir, together with NVIDIA and AWS, is creating a suite of Operations Co-Pilot solutions that will transform the operations management of telecom networks through intelligent automation. This new framework – built on NVIDIA Tensor Core GPUs and the NVIDIA AI Enterprise software platform for generative AI running on AWS – leverages Mavenir’s Open RAN architecture to provide accessibility into multiple open interfaces that can deliver the data needed to train and optimize domain-specific telecom LLMs.
Mavenir’s Chief Technology and Strategy Officer Bejoy Pankajakshan commented: “Our new Operations Co-Pilot framework has the potential to be a game-changer for operators, delivering a wealth of fault prediction and root cause analysis capabilities with AI-powered accuracy and speed. This industry-first solution is built on the transformative foundation of NVIDIA GPUs operating on AWS and enabled by Mavenir data, which can be accessed via numerous interfaces in the Open RAN and in the Packet Core for complete end-to-end visibility.”
He added: “The three key use cases of Core Dump Analysis, Log Similarity Search feature and Log Anomaly Detection can be used together to maximize the automated efficiency gains. Combining information from these trained LLMs will provide broader and deeper coverage of all fault and anomaly scenarios, enabling very early prediction of potential problems in the network. Moreover, as these solutions evolve, the models have the ability to continuously learn and optimize based on user feedback and iterative training with further logs, KPIs and traces, promising even greater gains.”
“In today’s fast-paced digital landscape, generative AI is a force multiplier for enterprises everywhere,” said Chris Penrose, global head of business development for telco at NVIDIA. “Mavenir’s framework, built on the NVIDIA AI Enterprise platform for streamlining the development and deployment of AI, will unlock a new level of operational efficiency for communications service providers.”
Notes to editors: Watch the video overview: Mavenir’s Operations Co-Pilot for RAN Service Assurance (RSA)
About Mavenir:
Mavenir is building the future of networks today with cloud-native, AI-enabled solutions which are green by design, empowering operators to realize the benefits of 5G and achieve intelligent, automated, programmable networks. As the pioneer of Open RAN and a proven industry disruptor, Mavenir’s award-winning solutions are delivering automation and monetization across mobile networks globally, accelerating software network transformation for 300+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. For more information, please visit www.mavenir.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240610302138/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom